Evidence map›Paper›PMID 34416084›Full record

Trial reportJournal of medical radiation sciences2021

Low-dose whole-lung irradiation in severe COVID-19 pneumonia: a controlled clinical trial.

Nima Mousavi Darzikolaee, Kasra Kolahdouzan, Hamidreza Abtahi, Hossein Kazemizadeh, Mohammadreza Salehi, Reza Ghalehtaki, Reyhaneh Bayani, Seyed Khalil Pestehei, Tooba Ghazanfari, Fatemeh Ebrahiminasab and 4 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of medical radiation sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Radiotherapy for non-cancer diseases: benefits and long-term risks.International journal of radiation biology · 2024
    Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Nima Mousavi DarzikolaeeRadiation Oncology Department, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Kasra KolahdouzanRadiation Oncology Department, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-1522-5619
Hamidreza AbtahiThoracic Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Hossein KazemizadehThoracic Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Mohammadreza SalehiDepartment of Infectious Diseases and Tropical Medicines, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Reza GhalehtakiRadiation Oncology Department, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Reyhaneh BayaniRadiation Oncology Department, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Seyed Khalil PesteheiImam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Tooba GhazanfariImmunoregulation Research Center, Shahed University, Tehran, Iran.
Fatemeh EbrahiminasabRadiation Oncology Department, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Samaneh SalarvandDepartment of Clinical and Anatomical Pathology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Peiman HaddadRadiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Ali KazemianRadiation Oncology Department, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Mahdi AghiliRadiation Oncology Department, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Imam Khomeini Hospital · IRTehran University of Medical Sciences · IRShahed University · IR

Funding

Tehran University of Medical Sciences 99-1-248-47528
6 · The paper itself

Abstract

introductionThe COVID-19 pandemic has caused significant morbidity and mortality thus far. Considering the historical uses of high-voltage X-ray beams for unresolvable pneumonia, we aimed to assess whether low-dose whole-lung irradiation (WLI) could provide any benefits for patients with refractory COVID-19 pneumonia.

methodsEleven patients with refractory COVID-19 pneumonia were treated with WLI to a total dose of 1 Gy and compared to 11 patients in a matched control group from June to November 2020. The study's primary endpoint was improvement of chest X-ray severity score (CXRS), followed by changes in mean oxygen (O2) saturation and 28-day mortality as secondary endpoints.

resultsThe final CXRS was significantly lower in the WLI group (8.7 ± 2.5) compared to the control group (12.3 ± 3.3) (P: 0.016). Change of CXRS from the first to the last chest X-ray was -2.2 ± 3.1 for the WLI group and 0.7 ± 3.9 for the control group, which showed a trend for lower CXRS in the WLI group (U = 30, p: 0.085). Mean O2 saturation showed insignificant improvement in the first 24 hours after radiotherapy (mean difference: 2.5 ± 4.1, Z=-1.6, P value: 0.11). Overall survival after 28 days was 32% in the WLI group and 11% in the control group (P: 0.48). The reason for death in many patients was not merely respiratory failure, but also other adverse situations like pneumothorax, cardiogenic shock and pulmonary thromboembolism.

conclusionsLow-dose WLI could improve the CXR severity score and O2 saturation in severely ill COVID-19 patients, but larger studies are required to determine its impact on mortality.

Indexed as

COVID-19HumansLungPandemicsSARS-CoV-2Treatment OutcomeCOVID-19radiotherapySARS-CoV-2whole-lung irradiation

Identifiers

PMID34416084
PMCPMC8427095
OpenAlexW3194284884

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.